Pulsheart Medical

medical devices

About

Sudden cardiac deaths (SCD), also known as sudden cardiac arrest, accounts for 10-15% of all deaths in adults (320 000-400 000 deaths each year in Europe) equivalent to the cumulative mortality of lung and breast cancers. The paradox is that efficient treatment options exist, such as implantable defibrillators. The major unsolved problem remains in how to non-invasively identify subjects at risk prior to death. Pulsheart was founded in 2023 By Prof. Michel Haïssaguerre and colleagues from the Liryc research center (159 international multidisciplinary experts in cardiology) to develop and validate software and hardware to tackle this major screening need, assess early a potential risk and prevent SCD.

Technologies

Gmail Google Apps

Keywords

medical equipment manufacturing medical devices cardiology research early screening tools machine learning risk stratification cardiac risk software validation risk prediction hardware software validation sudden cardiac death cardiology software risk prediction hardware development preventive cardiology hardware medical equipment and supplies manufacturing cardiology risk management cardiology screening medical technology implantable defibrillators medical device innovation clinical validation non-invasive risk assessment medical device development data analytics healthcare innovation cardiac risk detection healthcare medical hardware validation risk management cardiology research collaboration

Location

Avenue du Haut-Leveque, Pessac, Nouvelle-Aquitaine, France, 33600

Related Companies

Companies in the same industry